Top Story

Survival benefit of 9.2 million life-years attributed to Brazilian ART program

March 2, 2015

SEATTLE — Universal ART offered in Brazil from 1997 to 2014 is estimated to have a population survival benefit of 9.2 million life-years, according to data presented at CROI 2015.

“Brazil’s national policy of free-of-charge ART access to patients has led to dramatic survival benefits, the vast majority of which have yet to be realized,” the researchers wrote. “Higher CD4 counts at ART initiation and improvements in initial and subsequent ART regimens have all contributed substantially to these benefits.”

Meeting News Coverage

Average cost per SVR12 was $171,000 for Olysio, Sovaldi regimens

March 2, 2015
SEATTLE — The mean cost per sustained virologic response at 12 weeks among a cohort of patients with hepatitis C virus infection receiving treatment with Olysio…
Meeting News Coverage

Patients with HIV play key role in TB transmission

March 2, 2015
SEATTLE — In contrast to previous hypotheses, HIV-positive patients with pulmonary tuberculosis appear to have an important function in the onward transmission…
Meeting News Coverage

HIV did not affect HCC recurrence or survival after LT

March 2, 2015
Survival and recurrence rates were unaffected by HIV infection among patients who underwent liver transplantation for hepatocellular carcinoma, according to a poster…
In the Journals

Chronic fungal lesions predisposed to malignancy

March 2, 2015
Researchers in Brazil documented seven cases of squamous cell carcinoma that resulted from chronic chromoblastomycosis in the Brazilian Amazon state…
More News Headlines »
CME
Regimen Selection in HIV

Regimen Selection in HIV: Considering New Options to Optimize Outcomes
Monograph

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than 2 decades into the antiretroviral therapy (ART) era, numerous options are available for HIV treatment. The…
More »
Meeting News Coverage Video
thumbnail for video 4083320513001

Video: Highlights in cancer and HIV treatments at CROI 2015

February 27, 2015
Infectious Disease News Editorial Board member Paul Volberding, MD, reviews HIV and cancer treatment data presented…
More »
CME
HCV Consults: Volume 1, Number 3

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
morganatic-roan